Sign in
Taking peopleNo phase

Coil plus glue versus glue alone for bleeding stomach veins in cirrhosis

Compares two endoscopic treatments for bleeding gastric varices in people with cirrhosis.

Key facts

Who runs it
Medanta, The Medicity, India
Where
Orlando, United StatesSee the siteAlso in 1 other country, 1 site
Trial code
Registry title
EUS-Guided Coil and Glue vs Glue Injection for Bleeding Gastric Varices in Cirrhosis
Status
Recruiting
People taking part
110 people, planned
Started
Sept 2026
Expected to end
Jun 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • EUS-guided Coil and Cyanoacrylate Glue Injection
  • Endoscopic Cyanoacrylate Glue Injection
Record updated
6 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with liver cirrhosis and portal hypertension who may be bleeding from certain stomach veins (gastric varices). It compares two ways of closing these veins with glue, one also using coils.

Age
Over 18 years (minimum 19 years)
Sex
All sexes
Disease stage
Confirmed liver cirrhosis with portal hypertension (high pressure in the liver's blood vessels). Suspected bleeding from varices in the upper stomach, type GOV-2 or IGV-1.

Main reasons for not taking part

  • Bleeding from food-pipe varices (EV), GOV-1 or IGV2
  • Portal hypertension without cirrhosis
  • Blood actively spurting from the stomach varices at endoscopy
  • Pregnancy, shock that does not respond to treatment, sepsis or ACLF (sudden liver failure on top of long-term liver disease)
  • Platelet count < 50,000 /mL and INR > 2.0, or unable to have endoscopy

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age > 18 years
  • Confirmed diagnosis of liver cirrhosis with portal hypertension
  • Patients presenting with suspected bleed from cardio-fundal varices, specifically classified as gastroesophageal varices type-2 (GOV-2) or isolated gastric varices type-1 (IGV-1)

Who cannot take part

  • Patients experiencing bleeding from esophageal varices (EV) or gastroesophageal varices type-1 (GOV-1) or IGV2
  • Patients with non-cirrhotic portal hypertension
  • Platelet count < 50,000 /mL and International Normalized Rate (INR) > 2.0
  • Active spurt of blood noted from gastric varices seen on endoscopy
  • Pregnancy
  • Patients with refractory shock
  • Sepsis/ACLF
  • Contraindication to endoscopy
  • Not willing to provide consent

Where in United States

Also in 1 other country, 1 site

  • Orlando Health Orlando Regional Medical CenterOrlando, United StatesContact: Dr shyam, MDNot yet recruiting

About the trial

What the trial wants to find out

Gastric variceal bleeding is a life-threatening complication of portal hypertension in patients with cirrhosis and is associated with significant morbidity and mortality. Endoscopic cyanoacrylate glue injection is the current standard treatment; however, recurrent bleeding and procedure-related complications remain important concerns. Endoscopic ultrasound (EUS)-guided coil and cyanoacrylate glue injection has emerged as a promising alternative that may improve variceal obliteration and reduce rebleeding rates.

Read full original descriptionShow less

This prospective, randomized, open-label, parallel-group trial will compare EUS-guided coil and cyanoacrylate glue injection with conventional endoscopic cyanoacrylate glue injection in patients with cirrhosis presenting with bleeding gastric varices. A total of 158 participants will be randomized in a 1:1 ratio to either treatment arm. The primary outcome is all-cause rebleeding at 12 months. Secondary outcomes include technical success, early and late rebleeding, number of treatment sessions required for variceal obliteration, glue volume used, procedure-related adverse events, hepatic decompensation, duration of hospital stay, cost of treatment, and mortality.

The 2 groups in the trial

  • EUS-guided Coil and Glue InjectionTreatment being tested

    Participants randomized to this arm will undergo endoscopic ultrasound (EUS)-guided treatment of bleeding gastric varices using embolization coils followed by cyanoacrylate glue injection. Additional EUS-guided treatment will be performed during follow-up if residual Doppler flow is present until complete variceal obliteration is achieved. Participants will undergo scheduled follow-up for 12 months with clinical assessment, EUS surveillance, and laboratory investigations.

    Treatment: EUS-guided Coil and Cyanoacrylate Glue Injection

  • Endoscopic Glue InjectionExisting treatment, for comparison

    Participants randomized to this arm will undergo conventional endoscopic cyanoacrylate glue injection for treatment of bleeding gastric varices. Additional endoscopic glue injection will be performed during follow-up if residual varices are present until complete variceal obliteration is achieved. Participants will undergo scheduled follow-up for 12 months with clinical assessment, surveillance endoscopy, and laboratory investigations.

    Treatment: Endoscopic Cyanoacrylate Glue Injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Endoscopic Ultrasound-Guided Coil and Glue Injection Versus Endoscopic Glue Injection in Patients With Cirrhosis and Gastric Variceal Bleed: An Open Label Randomized Controlled Trial
Plain-language title
Coil plus glue versus glue alone for bleeding stomach veins in cirrhosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
6 October 2026